By By David Gutierrez, staff writer
(NaturalNews) On August 18, the FDA approved a drug for the controversial condition of female hypoactive sexual desire disorder. The drug, flibanserin (to be marketed as Addyi), had previously been rejected twice by the agency due to low effectiveness combined with a high risk of… |
Read more here: Natural News
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr